Endocrine Abstracts

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.

Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatment change: age, sex, time of diabetes evolution, Body mass index (BMI), abdominal perimeter (BP), systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL, HDL, triglycerides (TG), uric acid (UA). Statistical analysis: comparing means with Student’s test.

Results: 15 patients with DM-2 treated with metformin 1000 mg/12 h and liraglutide 1.8 mg with optimal glycemic control and stabilized weight loss. 60% women Age: 56±7.5 years. Time of diabetes evolution: 8±4.1 years. Weight loss achieved 6 months after the change of treatment was 9.7±11 Kg. No side effects were recorded. The treatment change was satisfactory for all patients.

Conclusions: The change of treatment of liraglutide 1.8 mg to dapagliflozin in patients with optimal glycemic control and stabilization weight loss, achieves a progression in weight loss and improves the metabolic control of the patient with DM-2. The change of treatment was satisfactory for all patients.